NASDAQ OMX

Kratos to Unveil Newest High Performance Class of Military Unmanned Aerial System Technology at 2017 Paris Air Show

13.6.2017 22:43 | NASDAQ OMX

Dela

Low-Cost, High-Performance Craft Represent Next Generation of Military Drones

SAN DIEGO, June 13, 2017 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS), a leading National Security Solutions provider, today announced the company will officially unveil a new class of unmanned aerial systems that represent the future of air combat at the 2017 Paris Air Show. Kratos is at the forefront of unmanned aerial systems with its ability to rapidly design, develop, demonstrate and deliver affordable high-performance jet powered drones.

Photos accompanying this announcement are available at 
http://www.globenewswire.com/NewsRoom/AttachmentNg/7d1c48b9-07d0-4ae1-9704-646f51a30f32 http://www.globenewswire.com/NewsRoom/AttachmentNg/96fb3aca-7dfe-470c-b662-436d7edd7286 http://www.globenewswire.com/NewsRoom/AttachmentNg/0a6629dc-e064-47b2-bb14-7909905913db http://www.globenewswire.com/NewsRoom/AttachmentNg/caf99365-ca62-415f-a9d3-205b812d0014

At the show, Kratos will be presenting the XQ-222 Valkyrie and UTAP-22 Mako drones that provide fighter-like performance and are designed to function as wingmen to manned aircraft in contested airspace.

The Valkyrie and the Mako represent the next generation of UAVs. They are highly maneuverable, stealthy, able to fly at near supersonic speeds, and can carry and deploy weapons or surveillance systems. The larger Valkyrie, measuring in at roughly 30 feet in length, has an impressive range of more than 3,000 nautical miles.

Most important, Kratos' UAVs are aligned with emerging military strategies because they are reusable and lower priced -- in the $2 million to $3 million range. This makes it cost efficient to deploy them in numbers that can effectively support manned aircraft or operate independently in combat.

The Valkyrie was recently announced by the Air Force Research Labs (AFRL) at a presentation on its Low Cost Attritable Aircraft Technology (LCAAT) program at Wright Patterson Air Force Base. 

"If you team up a bunch of these aircraft with an F-35 or an F-22, or some of our surveillance assets, you'd basically be able to cover more space at a lower cost point," Bill Baron, AFRL LCAAT project manager, told the Dayton Daily News at the May 9 event. "In a lot of cases, we don't have enough airplanes and as you look to the future, most likely our fleet sizes are going to continue to be more limited so this is a way to provide a force multiplier."

The Valkyrie has been in development since July 2016, when the U.S. Air Force awarded Kratos a contract to develop the LCAAT. After a less-than-two-year design and development effort, the Valkyrie is scheduled for its first flight in spring of 2018. The Mako is already operational and is scheduled for follow-on test flights, where it will carry sensors and be teamed with manned aircraft, in June, July and August of this year.

"The Mako and Valkyrie represent an entirely new category of UAVs," said Eric Demarco, Kratos CEO. "Thanks to our target drone expertise and our in-house research and development team, we have been able to combine high performance with low cost in fully functioning aircraft. And we did it in less than two years, not decades."

The Paris Air Show is the largest aerospace event in the world and will be held June 19-25. Kratos will be hosting visitors at booth # 3 A118.

About Kratos 
Kratos Defense & Security Solutions, Inc. (NASDAQ:KTOS) develops transformative technology for the Department of Defense and commercial customers. Kratos is changing the way breakthrough technology for these industries is brought to market through proactive research and a streamlined development process. Kratos specializes in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense and combat systems. For more information, go to www.kratosdefense.com

Press Contact:
Yolanda White
858-812-7302 Direct

Investor Information:
877-934-4687
investor@kratosdefense.com

Press Contact: 
Jon Schmid 
619-200-7257 
JSchmid@CookandSchmid.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Kratos Defense & Security Solutions, Inc. via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Skriv in din e-postadress så får du ett mejl när vi har något nytt att berätta.

Senaste nyheterna från NASDAQ OMX

Brand Industrial Services Announces Agreement to Acquire Venko Groep BV16.8.2017 19:40Pressmeddelande

Complementary core strengths provide broader range of services for customers KENNESAW, GA, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Brand Industrial Services, known as BrandSafway, has signed an agreement to acquire Venko Groep BV, a portfolio company of Mentha Capital. Venko will become a part of the Brand Energy & Infrastructure Services (Brand) group. "We are very pleased to announce the agreement with Venko," said Bill Hayes, President and CEO of BrandSafway. "Our combined customers in Europe will benefit from a broader range of solutions and greater depth of expertise in access, insulation and coatings. Bringing Venko's highly specialized knowledge in coatings to BrandSafway will provide the expertise we need to expand our services in the offshore market worldwide." Based in the Netherlands, with a focus on operations in the North Sea area, Venko is a leading offshore and onshore coatings maintenance provid

Abeona Therapeutics Announces Pivotal Expansion of ABO-102 Gene Therapy Clinical Trials in Sanfilippo Syndrome Type A16.8.2017 15:38Pressmeddelande

NEW YORK and CLEVELAND, Aug. 16, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced the pivotal expansion of its gene therapy clinical trials for patients with MPS IIIA in the USA, Europe and Australia. "We have completed the necessary regulatory and ethical committee approvals and site initiations in Europe and Australia in order to accelerate enrollment," stated Juan Ruiz, M.D., Ph.D., Abeona's Chief Medical Officer. "We remain very encouraged by the improvements observed in clinically relevant biomarkers post-dosing of ABO-102, including durable reductions in heparan sulfate measured in the CNS, reduction of organ disease pathology, and signals of CNS improvement or stabilization at one-year follow-up in Cohort 1 subjects, and look forward to providing a more fulsome clinical update at important clinical

CallidusCloud Wins Eight Gold Stevies® in the 2017 International Business Awards16.8.2017 14:00Pressmeddelande

CallidusCloud Lead to Money suite recognized as Best B2B New Product of the Year. LeadRocket voted Best New Product or Service of the Year in the Software - Lead Generation Solution category. DUBLIN, Calif., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Callidus Software Inc. (NASDAQ:CALD), a global leader in cloud-based sales, marketing, learning, and customer experience solutions, announced today that it was named the winner of eight Gold Stevie® awards in the 2017 International Business Awards. "The eight Stevie® awards earned highlight CallidusCloud's momentum, commitment to excellence, passion for innovation and customer orientation," said Leslie Stretch, president and CEO of CallidusCloud. "They also recognize the benefits that the Lead to Money suite, honored as the Best New Product in Business-to-Business, accrues to its customers in terms of enabling faster, bigger, and more profitable sales." CallidusCloud's Go

Ascom Myco and Koutio Médipôle optimize care communications and responsiveness16.8.2017 08:00Pressmeddelande

Ascom Holding AG / Ascom Myco and Koutio Médipôle optimize care communications and responsiveness . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. Enabled by the Ascom Myco smart device, the new Koutio Médipôle is realizing improved care delivery through seamless information flow from the point of care to anywhere. BAAR, Switzerland, Aug. 16, 2017 (GLOBE NEWSWIRE) -- The new Koutio Médipôle hospital in the New Caledonian capital Nouméa, located in the southwest Pacific Ocean, has optimized patient care communications and responsiveness for the new 645-bed facility by deploying Ascom Myco Wi-Fi devices to support clinician teams and Ascom Myco Wi-Fi/GSM handsets, used across paramedic teams. The Ascom solution is seamlessly aligned with clinical workflow and applications (nurs

VistaJet Harnesses the Power of the American Eclipse to Offer Customers a Rare Viewing Opportunity15.8.2017 18:40Pressmeddelande

VistaJet invites customers to fly in parallel with an astronomical anomaly NEW YORK, Aug. 15, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global aviation company, will be offering customers the opportunity to experience and chase the American Solar Eclipse, appearing for the first time in 99 years on August 21, 2017. A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/c0c41d7d-7ad9-4a46-9d2d-dcc1148b4772 The coast-to-coast National Eclipse and astronomical phenomenon will be visible in the United States from approximately 10:15AM PST, with the sun disappearing behind the moon from the Oregon coast, passing through 14 states to South Carolina.  Without being in this 70-mile strip, Americans will not be able to see the sun eclipsed in totality. With unparalleled experience flying into and out of the hardest to reach destinations, VistaJet is offer

NGX Bio Raises $3 Million to Fund Growth of Its DNA Sequencing Marketplace15.8.2017 17:00Pressmeddelande

SAN FRANCISCO, Aug. 15, 2017 (GLOBE NEWSWIRE) -- NGX Bio, Inc., (www.NGXbio.com) the premier marketplace for online DNA sequencing services, announced it has closed a $3 million funding round.  The round was led by 180 Degree Capital Corp. (NASDAQ:TURN) and included Third Kind Venture Capital, Lateral Capital, the Band of Angels and the Berkeley Angel Network, as well as other investors. NGX Bio was founded in 2014 to provide streamlined, on-line access to next-generation sequencing services for clients seeking high quality, rapid and cost-effective sequencing of both human and non-human samples globally.  Demand for sequencing services is growing exponentially.  NGX Bio's platform matches the sequencing needs of customers with providers who have available sequencing capacity.  Customers are able to purchase a wide range of sequencing services for their samples using NGX Bio's online ordering tools.  NGX Bio offers these services through numerous and deep relationships with its

I vårt nyhetsrum kan du läsa de senaste nyheterna, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt nyhetsrum